Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from Adaptive Biotechnologies and Amgen.
November 30, 2018
Lunch and registration: 12:30 PM – 1:30 PM
Marriott Marquis San Diego Marina
Lunch: Grand Ballroom 8-9
Meeting Room: Grand Ballroom 8-9
333 W. Harbor Drive
San Diego, CA 92101
Registration is complimentary, but seating is limited.
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy that can present at different stages of life. Great progress is being made with understanding of new cytogenetic and molecular abnormalities associated with ALL and its pathophysiology, as well as development of novel targeted agents for the treatment of patients with this disease. The addition of tyrosine kinase inhibitors, monoclonal antibodies, and novel immune therapies (eg, bispecific T-cell engager [BiTE], chimeric antigen receptor [CAR] T cells) to the treatment landscape has resulted in improved clinical outcomes. These new developments have shifted clinical management from a “one-size-fits-all” approach to a more individualized treatment approach based on immunophenotypic, cytogenetic, and molecular features. Optimal treatment strategies for ALL incorporate a multitude of factors that may be particularly challenging to implement for any busy clinician.
This Medical Crossfire® will provide an ideal format for you to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda centered on the contemporary management of patients with ALL. You will have the opportunity to absorb the perspectives of leading clinical experts on a variety of different patient scenarios, and to reflect on their handling of these cases as they integrate relevant evidence into real-world practice. You will also be able to compare your patient care approaches with those of the faculty and other participating clinicians. Faculty will discuss factors that may influence risk stratification and treatment decisions, methods to best integrate the latest therapies into ALL treatment paradigms, barriers to optimized integration of these novel agents, and best practices to assist you with the management of adverse events.
This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals interested in the latest advances in the treatment of patients with ALL. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.
After successful completion of this educational activity, participants should be better prepared to:
Elias Jabbour, MD
Associate Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018